How to use diuretics in heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 6, 2009, Pages 426-432

  Michael Felker, G ^a   Volz, Elizabeth M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BUMETANIDE; CONIVAPTAN; DIURETIC AGENT; DOFETILIDE; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LITHIUM; LOOP DIURETIC AGENT; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE;

ACUTE HEART FAILURE; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIURETIC ACTIVITY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENDOCRINE DISEASE; GYNECOMASTIA; HEART FAILURE; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMPOTENCE; LIBIDO; MASTALGIA; MENSTRUAL IRREGULARITY; METABOLIC ALKALOSIS; OTOTOXICITY; RENAL REPLACEMENT THERAPY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC HEART FAILURE;

EID: 70449487089     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0045-1     Document Type: Review

References (25)

1. D. Lloyd-Jones R. Adams M. Carnethon, et al. 2009 Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 e21 e181 19075105
2. K.F. Adams J. Lindenfeld J.M. Arnold, et al. 2006 HFSA 2006 Comprehensive Heart Failure Practice Guideline J Card Fail 12 1 119
3. B. Pitt F. Zannad W.J. Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 1:CAS:528:DyaK1MXmtVyrurk%3D 10471456
4. G.M. Felker C.M. O'Connor F.T. Braunwald 2009 Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2 56 62 19750134
5. G.S. Francis C. Benedict D.E. Johnstone, et al. 1990 Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive-heart-failure. A substudy of the Studies of Left-Ventricular Dysfunction (SOLVD) Circulation 82 1724 1729 1:STN:280:DyaK3M%2FivF2jug%3D%3D 2146040
6. G.S. Francis R.M. Siegel S.R. Goldsmith, et al. 1985 Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure. Activation of the neurohumoral axis Ann Intern Med 103 1 6 1:STN:280:DyaL2M3itlCrsA%3D%3D 2860833
7. H.A. Cooper D.L. Dries C.E. Davis, et al. 1999 Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction Circulation 100 1311 1315 1:STN:280:DyaK1MvitlKiuw%3D%3D 10491376
8. A. Ahmed A. Husain T.E. Love, et al. 2006 Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur Heart J 27 1431 1439 16709595
9. J. Butler D.E. Forman W.T. Abraham, et al. 2004 Relationship between heart failure treatment and development of worsening renal function among hospitalized patients Am Heart J 147 331 338 14760333 (Pubitemid 38176835)
10. V. Hasselblad W.G. Stough M.R. Shah, et al. 2007 Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial Eur J Heart Fail 9 1064 1069 1:CAS:528:DC%2BD2sXhtFWitr%2FJ 17719273
11. A. Herchuelz F. Derenne F. Deger, et al. 1989 Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance J Pharmacol Exp Ther 248 1175 1181 1:CAS:528:DyaL1MXhvVGgu78%3D 2703968
12. N.R. Loon C.S. Wilcox R.J. Unwin 1989 Mechanism of impaired natriuretic response to furosemide during prolonged therapy Kidney Int 36 682 689 1:STN:280:DyaK3c%2FktFygtg%3D%3D 2811065
13. B. Kaissling S. Bachmann W. Kriz 1985 Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment Am J Physiol 248 F374 F381 1:CAS:528:DyaL2MXhslyru70%3D 3976898
14. D.H. Ellison 2001 Diuretic therapy and resistance in congestive heart failure Cardiology 96 132 143 1:CAS:528:DC%2BD38XmtFKguw%3D%3D 11805380
15. Salvator DR, Rey NR, Ramos GC, Punzalan FE: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, CD003178.
16. M. Jessup W.T. Abraham D.E. Casey, et al. 2009 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 1977 2016 19324967
17. D.N. Juurlink M.M. Mamdani D.S. Lee, et al. 2004 Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 543 551 1:CAS:528:DC%2BD2cXmtF2rtb0%3D 15295047
18. B. Pitt W. Remme F. Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 1:CAS:528:DC%2BD3sXis1ehurY%3D 12668699
19. Canadian Cardiovascular Society American Academy of Family Physicians American College of Cardiology American Heart Association E.M. Antman M. Hand P.W. Armstrong, et al. 2008 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 210 247 18191746
20. K.S. Channer K.A. McLean P. Lawson-Matthew M. Richardson 1994 Combination diuretic treatment in severe heart failure: a randomised controlled trial Br Heart J 71 146 150 1:STN:280:DyaK2c7ns1aktA%3D%3D 8130022
21. M. Gheorghiade M.A. Konstam J.C. Burnett Jr, et al. 2007 Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 1332 1343 1:CAS:528:DC%2BD2sXjs1ejt7k%3D 17384438
22. M.A. Konstam M. Gheorghiade J.C. Burnett Jr, et al. 2007 Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 1319 1331 1:CAS:528:DC%2BD2sXjs1ejtrg%3D 17384437
23. G. Cotter H.C. Dittrich B.D. Weatherley, et al. 2008 The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 631 640 1:CAS:528:DC%2BD1cXhtFOrtLvK 18926433
24. S.S. Gottlieb D.C. Brater I. Thomas, et al. 2002 BG9719 (CVT-124), an A(1) adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 1348 1353 1:CAS:528:DC%2BD38XjtFalsL4%3D 11901047
25. M.R. Costanzo M.E. Guglin M.T. Saltzberg, et al. 2007 Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 675 683 1:CAS:528:DC%2BD2sXhs1Slt7g%3D 17291932